Genzyme ran into a snag in April when the US Food and Drug Administration (FDA) rejected its application to produce Myozyme (alglucosidase alfa, rhGAA) in its 2,000–liter-scale facility under ...
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director ...
Genzyme continued to drive growth for Sanofi ... analysts predicting sales of several billion dollars a year for the drug. Sanofi said the consolidation of Bioverativ, the haemophilia specialist ...
BMS refiled quickly, but was given an FDA action date of 27 March 2021 ... for example in the wake of Sanofi’s takeover of Genzyme in 2011, which also included a CVR tied to the approval ...
Other prior executive leadership roles include developing and launching innovative therapies for specialty care and rare disease indications at Sobi, Amgen, and Genzyme. Furthermore, she has ...
The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...
Brian Pacheco New York The writer is the managing director of communications for the Drug Policy Alliance. To the Editor: Nicholas Kristof’s column starts with a faulty and harmful premise ...
Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. A sustained ...
JMB’s institution has received funding from Genzyme, and EyeGuide supporting his work, and he has served as a paid consultant to Med-IQ and Sporting KC. JSB reports receiving methods author funding ...
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback